TREML2, Recombinant, Human (Triggering Receptor Expressed on Monocytes Cells-like Protein 2, TREM-li

Trem­like transcript 2 protein (TLT­2, also TREML2) is a 33kD (unglycosylated) type I transmembrane cell surface receptor and member of the Trem family of receptor proteins. Human TLT­2 is synthesized as a 321aa precursor that contains an 18 aa signal sequence, a 250aa extracellular domain (ECD), a 21aa transmembrane segment, and a 32aa cytoplasmic tail (SwissProt # Q5T2D2). Within the ECD are an Ig­like V­type domain (aa20­121) and one potential site of N­linked glycosylation. Mature human TLT­2 shares 49% aa sequence identity with mature mouse TLT­2. Cell surface expression of TLT­2 is seen for most of the B and myeloid cell lines. TLT­2 is also expressed constitutively on CD8+ T cells and induced on CD4+ T cells after activation. TLT­2 plays a role in the innate and adaptive immune responses. In 2008, Hashiguchi et al. discovered that the B7 family member B7­H3, which also plays important roles in immune responses, specifically bound to TLT­2. According to their research, stimulation with B7­H3 transfectants preferentially up­regulated the proliferation and IFN-gamma production on CD8+ T cells. Also, transduction of TLT­2 into T cells resulted in enhanced IL­2 and IFN-gamma production via interactions with B7­H3, and blockade of the B7­H3:TLT­2 pathway with mAb against B7­H3 or TLT­2 efficiently inhibited contact hypersensitivity responses. In 2009, however, Leitner et al. extensively analyzed interaction of B7­H3 with TLT­2 and found no evidence for such an interaction. Source: Murine myeloma cell line, NS0­derived Human TREML2 (Gly78-Ser327). SDS-PAGE: 75-100kD, reducing conditions, Activity: Measured by its ability to inhibit anti­CD3­induced proliferation of stimulated human T cells. Human PBMC cultured for 72 hours with PHA were incubated for an additional 3 days in 96 well plates coated with anti­CD3 and recombinant human TREML2/Fc Chimera. The ED50 for this effect is typically 0.45-1.8ug/ml. Endotoxin Level: <1EU/1ug (LAL) , Storage and Stability:, Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with sterile ddH2O or PBS. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Reconstituted product is stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.